AAPS PharmSciTech

, 20:99 | Cite as

Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines

  • Li Chen
  • Hamad Alrbyawi
  • Ishwor Poudel
  • Robert D. Arnold
  • R. Jayachandra BabuEmail author
Research Article Theme: Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems
Part of the following topical collections:
  1. Theme: Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems


This study reports co-delivery of doxorubicin (DOX) and ceramide in a liposomal system in B16BL6 melanoma cell lines for enhanced cytotoxic effects. Different types of ceramides (C6-ceramide, C8-ceramide, and C8-glucosylceramide) and lipids (1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)) were considered in the preparation of liposomes. DOX was encapsulated within liposome, and ceramide was used as the component of the lipid bilayer. The formulations were optimized for size and size distribution, zeta potential, and DOX encapsulation efficiency (EE). Cytotoxic effect on B16BL6 melanoma cell lines was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The ceramide based liposome formulations generally provided a mean diameter < 181 nm, a zeta potential, + 35 mV, and EE > 90% DOX EE. Co-delivery of DOX and C8-ceramide with DOTAP liposomes demonstrated significantly higher cytotoxicity as compared to DOX liposomes without ceramide (P < 0.001), and also showed enhanced cellular uptake by B16BL6 cell lines. This study provides basis for developing a co-delivery system of DOX and ceramide for lowering the dose and dose-related side effects of DOX for the treatment of melanoma.


doxorubicin liposome formulation ceramide melanoma cytotoxicity 


Funding Information

This work received financial support from Auburn University Research Initiative in Cancer (AURIC) and the intramural grant program (IGP) from the Auburn University AL.


  1. 1.
    Gniadecka M, Philipsen PA, Wessel S, Gniadecki R, Wulf HC, Sigurdsson S, et al. Melanoma diagnosis by Raman spectroscopy and neural networks: structure alterations in proteins and lipids in intact cancer tissue. J Investig Dermatol. 2004;122(2):443–9.PubMedGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics for hispanics/latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98.PubMedGoogle Scholar
  3. 3.
    Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851–7.PubMedGoogle Scholar
  4. 4.
    Megahed AI, Koon HB. What is the role of chemotherapy in the treatment of melanoma? Curr Treat Options in Oncol. 2014;15(2):321–35.Google Scholar
  5. 5.
    Matos AM, Francisco AP. Targets, structures, and recent approaches in malignant melanoma chemotherapy. ChemMedChem. 2013;8(11):1751–65.PubMedGoogle Scholar
  6. 6.
    Arienti C, Zoli W, Pignatta S, Carloni S, Paganelli G, Ulivi P, et al. Efficacy of different sequences of radio-and chemotherapy in experimental models of human melanoma. J Cell Physiol. 2014;229(10):1548–56.PubMedGoogle Scholar
  7. 7.
    Hao MZ, Zhou WY, Du XL, Chen KX, Wang GW, Yang Y, et al. Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer. 2014;33(9):458–65.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Qu X, Felder MA, Horta ZP, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013;17(4):1141–7.PubMedGoogle Scholar
  9. 9.
    Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res. 2014;306(6):521–6.PubMedGoogle Scholar
  10. 10.
    Kudriavtsev DV, Kudriavtseva GT, Mardynskiĭ I. Adjuvant chemotherapy as a component of complex treatment for skin melanoma. Vopr Onkol. 2008;54(2):170–7.PubMedGoogle Scholar
  11. 11.
    Luke JJ, Schwartz GK. Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol. 2013;31(3):290–7.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Szwed M, Laroche-Clary A, Robert J, Jozwiak Z. Induction of apoptosis by doxorubicin–transferrin conjugate compared to free doxorubicin in the human leukemia cell lines. Chem Biol Interact. 2014;220:140–8.PubMedGoogle Scholar
  13. 13.
    Rocconi RP, Straughn JM, Leath CA, Kilgore LC, Huh WK, Barnes MN, et al. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist. 2006;11(4):336–41.PubMedGoogle Scholar
  14. 14.
    Petznek H, Kleiter M, Tichy A, Fuchs-Baumgartinger A, Hohenadl C. Murine xenograft model demonstrates significant radio-sensitising effect of liposomal doxorubicin in a combination therapy for feline injection site sarcoma. Res Vet Sci. 2014;97(2):386–90.PubMedGoogle Scholar
  15. 15.
    Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep. 1986;70(1):51–63.PubMedGoogle Scholar
  16. 16.
    Wadler SC, Yang CP. Reversal of doxorubicin resistance by hydrophobic, but not hydrophilic, forskolins. Mol Pharmacol. 1991;40(6):960–4.PubMedGoogle Scholar
  17. 17.
    Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(19):3159–65.PubMedGoogle Scholar
  18. 18.
    Speelmans G, Staffhorst RW, de Kruijff B, de Wolf FA. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflet of the plasma membrane. Biochemistry. 1994;33(46):13761–8.PubMedGoogle Scholar
  19. 19.
    Zheng L, Gou M, Zhou S, Yi T, Zhong Q, Li Z, et al. Antitumor activity of monomethoxy poly (ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma. Oncol Rep. 2011;25(6):1557–64.PubMedGoogle Scholar
  20. 20.
    Jones AK, Bejugam NK, Nettey H, Addo R, D’Souza MJ. Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. J Drug Target. 2011;19(6):427–33.PubMedGoogle Scholar
  21. 21.
    Lohade AA, Jain RR, Iyer K, Roy SK, Shimpi HH, Pawar Y, et al. A novel folate-targeted nanoliposomal system of doxorubicin for cancer targeting. AAPS PharmSciTech. 2016;17(6):1298–311.PubMedGoogle Scholar
  22. 22.
    Dash TK, Konkimalla VB. Formulation and optimization of doxorubicin and biochanin a combinational liposomes for reversal of chemoresistance. AAPS PharmSciTech. 2017;18(4):1116–24.PubMedGoogle Scholar
  23. 23.
    Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig. 2001;19(4):424–36.Google Scholar
  24. 24.
    Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71–97 Academic Press.PubMedGoogle Scholar
  25. 25.
    Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11(8):1029–33.PubMedGoogle Scholar
  26. 26.
    Bendle M, Pealing J, Papanastasopoulos P, Bower M. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi’s sarcoma (KS). Cancer Chemother Pharmacol. 2014;74(3):611–5.PubMedGoogle Scholar
  27. 27.
    Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet™). Breast. 2009;18(4):218–24.PubMedGoogle Scholar
  28. 28.
    Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, et al. Nanomedicines: from bench to bedside and beyond. AAPS J. 2016;18(6):1373–8.PubMedGoogle Scholar
  29. 29.
    Burenjargal M, Lee YS, Yoo JM, Kim YC, Lee YM, Oh S, et al. Endogenous sphingolipid metabolites related to the growth in Sphingomonas chungbukensis. Arch Pharm Res. 2007;30(3):317–22.PubMedGoogle Scholar
  30. 30.
    Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274(5294):1855–9.PubMedGoogle Scholar
  31. 31.
    Kolesnick RN, Krönke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol. 1998;60(1):643–65.PubMedGoogle Scholar
  32. 32.
    Radin NS. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur J Biochem. 2001;268(2):193–204.PubMedGoogle Scholar
  33. 33.
    Johns DG, Charpie JR, Webb RC. Is ceramide signaling a target for vascular therapeutic intervention? Curr Pharm Des. 1998;4(6):481–8.PubMedGoogle Scholar
  34. 34.
    Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta Biomembr. 2003;1612(1):98–106.Google Scholar
  35. 35.
    Shabbits JA, Mayer LD. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res. 2003;23(5A):3663–9.PubMedGoogle Scholar
  36. 36.
    Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther. 2003;307(2):468–75.PubMedGoogle Scholar
  37. 37.
    Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008;14(11):3571–81.PubMedGoogle Scholar
  38. 38.
    Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, et al. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J Pharmacol Exp Ther. 2005;315(2):704–10.PubMedGoogle Scholar
  39. 39.
    Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, et al. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017;8(44):76921–34.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Sriraman SK, Pan J, Sarisozen C, Luther E, Torchilin V. Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: in vitro evaluation on HeLa, A2780-ADR, and H69-AR cells. Mol Pharm. 2016;13(2):428–37.PubMedGoogle Scholar
  41. 41.
    Zhai L, Sun N, Han Z, Jin HC, Zhang B. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo. Biochem Biophys Res Commun. 2015;468(1):274–80.PubMedGoogle Scholar
  42. 42.
    Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. J Control Release. 2014;196:122–31.PubMedGoogle Scholar
  43. 43.
    Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta Biomembr. 1993;1151(2):201–15.Google Scholar
  44. 44.
    Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta Biomembr. 2006;1758(10):1633–40.Google Scholar
  45. 45.
    Wang Y, Chen L, Ding Y, Yan W. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Int J Pharm. 2012;422(1–2):409–17.PubMedGoogle Scholar
  46. 46.
    Wang Y, Ding Y, Liu Z, Liu X, Chen L, Yan W. Bioactive lipids-based pH sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia. Pharm Res. 2013;30(11):2902–16.PubMedGoogle Scholar
  47. 47.
    Sudimack JJ, Guo W, Tjarks W, Lee RJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta Biomembr. 2002;1564(1):31–7.Google Scholar
  48. 48.
    Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res. 1992;52(9):2431–9.PubMedGoogle Scholar
  49. 49.
    Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta Biomembr. 2004;1663(1):167–77.Google Scholar
  50. 50.
    Zheng RR, Hu W, Sui CG, Ma N, Jiang YH. Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells. Oncol Rep. 2014;32(6):2719–25.PubMedGoogle Scholar
  51. 51.
    Shavit L, Lifschitz MD, Gabizon A, Kwa M, Muggia F, Slotki I. Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. Kidney Int. 2014;85(1):213.PubMedGoogle Scholar
  52. 52.
    Zhao JY, Ma XL, Li ZM, Deng R, Wang SM, Shen GB, et al. Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction. Clin Exp Med. 2015;15(2):127–35.PubMedGoogle Scholar
  53. 53.
    Mittal A, Tabasum S, Singh RP. Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft. Phytomedicine. 2014;21(3):340–7.PubMedGoogle Scholar
  54. 54.
    Gabizon A, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci. 2012;45(4):388–98.PubMedGoogle Scholar
  55. 55.
    Ke X, Bei JH, Zhang Y, Li J. In vitro and in vivo evaluation of sanguinarine liposomes prepared by a remote loading method with three different ammonium salts. Pharmazie. 2011;66(4):258–63.PubMedGoogle Scholar
  56. 56.
    Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci. 1987;84(21):7413–7.PubMedGoogle Scholar
  57. 57.
    Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res. 1998;4(2):499–505.PubMedGoogle Scholar
  58. 58.
    Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409–19.PubMedGoogle Scholar
  59. 59.
    Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–34.PubMedGoogle Scholar
  60. 60.
    La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2012;69(1):43–50.PubMedGoogle Scholar
  61. 61.
    Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials. 2013;34(34):8718–25.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Lowery A, Onishko H, Hallahan DE, Han Z. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release. 2011;150(1):117–24.PubMedGoogle Scholar
  63. 63.
    van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 2011;25(1):280–9.PubMedGoogle Scholar
  64. 64.
    Han WS, Yoo JY, Youn SW, Kim DS, Park KC, Kim SY, et al. Effects of C2-ceramide on the Malme-3M melanoma cell line. J Dermatol Sci. 2002;30(1):10–9.PubMedGoogle Scholar
  65. 65.
    London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts) implications for lipid raft structure and function. J Biol Chem. 2004;279(11):9997–10004.PubMedGoogle Scholar
  66. 66.
    Delpy E, Hatem SN, Andrieu N, de Vaumas C, Henaff M, Rücker-Martin C, et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res. 1999;43(2):398–407.PubMedGoogle Scholar
  67. 67.
    Martínez R, Navarro R, Lacort M, Ruiz-Sanz JI, Ruiz-Larrea MB. Doxorubicin induces ceramide and diacylglycerol accumulation in rat hepatocytes through independent routes. Toxicol Lett. 2009;190(1):86–90.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Li Chen
    • 1
  • Hamad Alrbyawi
    • 1
    • 2
  • Ishwor Poudel
    • 1
  • Robert D. Arnold
    • 1
  • R. Jayachandra Babu
    • 1
    Email author
  1. 1.Department of Drug Discovery and Development, Harrison School of PharmacyAuburn UniversityAuburnUSA
  2. 2.Pharmaceutics and Pharmaceutical Technology Department, College of PharmacyTaibah UniversityMedinaSaudi Arabia

Personalised recommendations